AL

Anker Lundemose

Chief Executive Officer

Mission Therapeutics

Cambridge, England


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Mission Therapeutics
Industry
research
Employees
20.0
Seniority
C suite
Annual Revenue
40100000.0
Total Funding
174015311.0
Latest Funding
Other

Technologies

Outlook WordPress.org YouTube Google Font API Typekit Mobile Friendly Wistia Vimeo Remote Circle AI

Keywords

drug discovery oncology neurodegeneration ubiquitin deubiquitylating enzymes cancer biotechnology research dub drug discovery mitophagy neurodegenerative diseases disease-modifying treatment usp30 clinical development small molecule inhibitors therapeutic targets heart failure parkinsons disease rare mitochondrial diseases fibrosis pipeline clinical candidates first-in-class therapeutics cellular quality control investors collaborative research drug candidates disease-associated dubs scientific culture patient-focused venture capital biotechnology molecular biology drug development biotech innovation research partnerships safety & efficacy biological assays preclinical studies clinical trials academic collaborations fda approval medical breakthroughs targeted therapies protein homeostasis ubiquitin pathway cell health research & development high-impact journals ptential partnerships disruptive biotechnology biopharmaceuticals life sciences drug commercialization therapeutic pipelines patient selection strategy sustainable innovation hospital & health care health care health wellness & fitness

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans